Mazdutide Ameliorates Non-Alcoholic Fatty Liver Disease by Modulating Endoplasmic Reticulum Stress
Mazdutide shows potential in ameliorating NAFLD symptoms in preclinical models by improving lipid metabolism and reducing inflammation, but human studies are needed to confirm these findings.
Where it sits
this study against the rest of the mazdutide (ibi362) corpusSummary and findings
Mazdutide was tested in a NAFLD mouse model and a cellular model to assess its effects on lipid metabolism and inflammation. Mice were treated with Mazdutide at doses of 100, 200, or 400 μg/kg for 4 weeks. The study found improvements in lipid metabolism, liver injury markers, and inflammation.
Abstract
<h4>Background: </h4> Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disorder globally. Mazdutide has shown clinical benefits in weight management and metabolic regulation, indicating its potential as a therapeutic agent for NAFLD. This study aimed to investigate the efficacy and mechanism of action of Mazdutide against early-stage NAFLD. <h4>Methods:</h4> A NAFLD mouse model was induced by a 12-week high-fat diet, followed by a 4-week treatment with subcutaneous Mazdutide (100, 200, or 400 μg/kg). In vitro, a cellular NAFLD model was established by treating hepatocytes with 1 mM free fatty acids for 24 h, followed by co-treatment with Mazdutide (10, 20, or 50 nM) or the endoplasmic reticulum (ER) stress inhibitor 4-phenylbutyric acid (4-PBA). Serum and hepatic lipid profiles, liver injury markers, and pro-inflammatory cytokines were quantified. Liver histopathology was assessed by hematoxylin and eosin and Oil Red O staining. Protein expression related to ER stress, inflammation, and lipid metabolism was analyzed by immunohistochemistry and Western blot. <h4>Results:</h4> Mazdutide treatment significantly ameliorated systemic and hepatic lipid metabolism disorders, reduced liver injury markers and hepatic steatosis, and mitigated inflammation and oxidative stress in NAFLD mice and hepatocytes. Mechanistically, Mazdutide alleviated ER stress by modulating the PERK-eIF2α-ATF4-CHOP pathway, suppressed the NF-κB-mediated inflammatory response, and downregulated key lipogenic regulators, including SREBP-1, C/EBPβ, and PPARγ. <h4>Conclusion:</h4> Our findings demonstrate that Mazdutide alleviates hepatic ER stress in NAFLD, leading to suppressed inflammatory responses and improved lipid metabolism, which ultimately attenuates disease progression.
Background
Non-alcoholic fatty liver disease (NAFLD) is a widespread chronic liver condition with limited effective treatments. Mazdutide has previously shown promise in weight management and metabolic regulation, suggesting potential benefits for NAFLD. This study explores Mazdutide's efficacy and mechanisms in addressing early-stage NAFLD, focusing on its impact on lipid metabolism and endoplasmic reticulum (ER) stress.
Methods
The study utilized a NAFLD mouse model induced by a 12-week high-fat diet, followed by a 4-week treatment with subcutaneous Mazdutide at doses of 100, 200, or 400 μg/kg. An in vitro cellular model was also used, where hepatocytes were treated with 1 mM free fatty acids and co-treated with Mazdutide or an ER stress inhibitor. Outcomes measured included serum and hepatic lipid profiles, liver injury markers, pro-inflammatory cytokines, and protein expression related to ER stress, inflammation, and lipid metabolism.
Results
Mazdutide treatment resulted in significant improvements in systemic and hepatic lipid metabolism, reduced liver injury markers, and decreased hepatic steatosis. The treatment also mitigated inflammation and oxidative stress in both NAFLD mice and hepatocytes. Mechanistically, Mazdutide alleviated ER stress by modulating the PERK-eIF2α-ATF4-CHOP pathway and suppressed the NF-κB-mediated inflammatory response, along with downregulating key lipogenic regulators.
Interpretation
The findings suggest that Mazdutide has a beneficial effect on NAFLD by improving lipid metabolism and reducing inflammation through modulation of ER stress pathways. While the results are promising, the study's reliance on animal and in vitro models limits its direct clinical applicability. Further research in human subjects is necessary to confirm these effects and assess clinical significance.
Key findings
- Mazdutide significantly ameliorated systemic and hepatic lipid metabolism disorders.
- Reduced liver injury markers and hepatic steatosis were observed.
- Inflammation and oxidative stress were mitigated in NAFLD mice and hepatocytes.
- Mazdutide modulated the PERK-eIF2α-ATF4-CHOP pathway.
- Suppressed NF-κB-mediated inflammatory response was noted.
Limitations
- Animal model study, not human data.
- In vitro cellular model used.
- Specific numeric results not detailed.
- Short 4-week treatment duration.